La Jolla Institute, RevolKa Collaborate on Next-Gen Vaccine Antigens

Facebook
Pinterest
Twitter
LinkedIn

La Jolla Institute for Immunology, a world-renowned research institute, and RevolKa Ltd., an innovative biotech company with a cutting-edge protein engineering technology platform, have announced a groundbreaking research collaboration. This partnership aims to develop next-generation vaccine antigens that will revolutionize the fight against infectious diseases.

By combining La Jolla Institute for Immunology’s expertise in immunology research and RevolKa’s advanced protein engineering capabilities, the collaboration seeks to create novel solutions for unmet medical needs in the field of infectious diseases. The synergy between these two organizations holds immense potential for delivering transformative vaccines that will protect global populations from emerging threats.